Literature DB >> 3274046

Heterozygosity at the Km locus associated with humoral immunity to Campylobacter jejuni.

J P Pandey1, M J Blaser.   

Abstract

Serum samples from 43 Caucasian subjects convalescing from acute Campylobacter jejuni infection were typed for nine Gm and two Km determinants. The sera were also used to measure IgA, IgG, and IgM classes of antibody to acid-labile surface proteins of C. jejuni by an enzyme-linked immunosorbent assay. A highly significant association (p = 0.004) was found between Km1/Km3 heterozygotes and the level of IgA antibodies. These results suggest the existence of complementary immune response genes which in the heterozygous condition permit a humoral response to C. jejuni.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3274046

Source DB:  PubMed          Journal:  Exp Clin Immunogenet        ISSN: 0254-9670


  5 in total

1.  Immunoglobulin KM genes in Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Christian A Vedeler
Journal:  Neurogenetics       Date:  2003-02-11       Impact factor: 2.660

2.  Immunoglobulin kappa chain allotypes (KM) in onchocerciasis.

Authors:  J P Pandey; L H Elson; S E Sutherland; R H Guderian; E Araujo; T B Nutman
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Michiaki Koga; Nobuhiro Yuki
Journal:  Neurogenetics       Date:  2005-10-29       Impact factor: 2.660

4.  Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Jacquie Astemborski; David L Thomas
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits.

Authors:  C W Ang; P G Noordzij; M A de Klerk; H P Endtz; P A van Doorn; J D Laman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.